AAIC 2025 Abstract
Clinical evidence and biological considerations in the clinical use of lecanemab – experience at an academic medical center
Study in peopleInterventions
Abstract
Background: Lecanemab and donanemab are anti‐amyloid antibodies proven in 18‐month clinical trials to slow progression of early Alzheimer's disease by biomarker, cognitive and functional measures. While both are now approved in many countries, lecanemab was first USA‐approved in January2023, and Medicare‐covered since July2023.
